Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study  by Rich, Michael W et al.
Effect of Age on Mortality,
Hospitalizations and Response to Digoxin
in Patients With Heart Failure: The DIG Study
Michael W. Rich, MD, FACC,* Frances McSherry, MS,† William O. Williford, PHD,†
Salim Yusuf, MD, FACC,‡ for the Digitalis Investigation Group
St. Louis, Missouri; Perry Point, Maryland; and Toronto, Ontario, Canada
OBJECTIVES This study was designed to determine the effect of increasing age on mortality, hospitaliza-
tions and digoxin side effects in patients with heart failure (HF), and to determine whether
the effect of digoxin on clinical outcomes varies as a function of age.
BACKGROUND The incidence and prevalence of HF increase with advancing age, but there are limited data
on the clinical course and response to specific therapeutic interventions in elderly patients
with HF.
METHODS The Digitalis Investigation Group (DIG) study was a prospective, randomized clinical trial
involving 7,788 patients with HF randomized to digoxin or placebo and followed for an
average of 37 months. In the present analysis, patients were stratified into five age categories:
,50 years (n 5 841), 50 to 59 years (n 5 1,545), 60 to 69 years (n 5 2,885), 70 to 79 years
(n 5 2,092) and $80 years (n 5 425). Interactions between age and the following clinical
outcomes were examined: total mortality, all-cause hospitalizations, HF hospitalizations, the
composite of HF death or HF hospitalization, hospitalization for suspected digoxin toxicity
and withdrawal from therapy because of side effects.
RESULTS Increasing age was an independent risk factor for total mortality, all-cause hospitalization, HF
hospitalization, HF death or hospital admission, hospitalization for suspected digoxin toxicity
and withdrawal from digoxin therapy (all p , 0.001). However, there were no significant
interactions between age and digoxin treatment with respect to any of the major clinical end
points.
CONCLUSIONS Increasing age is associated with progressively worse clinical outcomes in patients with HF.
However, the beneficial effects of digoxin in reducing all-cause admissions, HF admissions,
and HF death or hospitalization are independent of age. Thus, digoxin remains a useful agent
for the adjunctive treatment of HF due to impaired left ventricular systolic function in
patients of all ages. (J Am Coll Cardiol 2001;38:806–13) © 2001 by the American College
of Cardiology
Both the incidence and prevalence of heart failure (HF)
increase progressively with advancing age (1), and individ-
uals over 65 years of age account for 79% of all hospitaliza-
tions and 88% of all deaths attributable to HF (2,3).
Moreover, it is anticipated that the societal burden of HF
will continue to increase as the population ages. However,
despite the fact that HF is predominantly a disorder of the
elderly, there are limited data on the clinical course, prog-
nosis and response to specific therapeutic interventions in
older patients, particularly those over the age of 80 years.
The Digitalis Investigation Group (DIG) study was a
prospective, randomized, double-blind placebo-controlled
clinical trial designed to evaluate the effects of digoxin on
mortality and hospitalizations in patients with chronic HF
and sinus rhythm (4). Treatment was administered on a
background of diuretic and angiotensin-converting enzyme
(ACE) inhibitor therapy. A total of 7,788 patients were
enrolled in the trial, including 6,800 with a left ventricular
ejection fraction (LVEF) of #0.45 (main trial), and 988
with an LVEF .0.45 (ancillary trial). The mean age of
patients in the study was 63.9 years, and 32% were 70 years
of age or older. Mean follow-up was 37 months and the
primary trial end point was all-cause mortality. The princi-
pal finding of the DIG study was that although digoxin had
no discernible effect on total mortality, the composite end
point of HF death or hospitalization was reduced 24% (95%
confidence interval 18% to 30%; p , 0.001) in patients
randomized to digoxin treatment (4).
The purpose of the present analysis was to examine the
effect of age on clinical outcomes, including mortality,
hospitalizations and adverse drug reactions, and to deter-
mine whether the response to digoxin varied with age.
METHODS
The rationale, design and main results of the DIG study
have been previously published (4,5). Briefly, patients with
chronic HF based on clinical symptoms, signs and radio-
graphic findings, and who were in sinus rhythm, were
randomized to digoxin or matching placebo at 302 centers
in the U.S. and Canada. Patients were stratified according
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to LVEF (#0.45 or .0.45), as assessed by radionuclide
angiography, contrast ventriculography or echocardiogra-
phy. Angiotensin-converting enzyme inhibitor therapy was
recommended for all patients with an LVEF #0.45, and
more than 93% of all DIG participants received such
treatment. The digoxin dose was determined using a stan-
dardized algorithm based on age, gender, weight and renal
function. The median dose of digoxin was 0.25 mg, the
mean steady-state digoxin level at one-month follow-up was
0.89 6 0.50 ng/ml and 87% of patients in the digoxin group
had digoxin levels within the therapeutic range at the
one-month follow-up visit. The DIG study was approved
by the institutional review boards at all participating centers,
and all patients provided written informed consent.
The primary outcome for the DIG study was all-cause
mortality. Secondary outcomes were cardiovascular mortal-
ity, death from worsening HF, hospitalization due to
worsening HF and hospitalization for other reasons, includ-
ing suspected digoxin toxicity. Data were reviewed at
six-month intervals by an independent Data and Safety
Monitoring Board. The trial was terminated as planned on
December 31, 1995, after a mean follow-up of 37 months
(range 28 to 58 months). When the main results of the trial
were reported, the vital status was unknown in 1.4% of
patients, and data on these patients were censored at the
date of the last known follow-up visit.
In the present analysis, all 7,788 DIG study patients were
retrospectively grouped into five age categories: ,50 years
(n 5 841), 50 to 59 years (n 5 1,545), 60 to 69 years (n 5
2,885), 70 to 79 years (n 5 2,092) and $80 years (n 5 425).
Total mortality, all-cause hospitalizations, HF hospitaliza-
tions and the combined end point of HF death or HF
hospitalization were determined within each age group,
both overall and within subgroups according to treatment
assignment. Because there was no heterogeneity in the effect
of digoxin on any of these end points with respect to LVEF
#0.45 or .0.45, data from the main and ancillary trials
were pooled for the present analysis.
Statistics. The Mantel-Haenszel statistic was used to test
for linear association between age and each of the above
outcomes, and for the association between age and adverse
drug reactions, defined as drug withdrawal because of side
effects or hospitalization for suspected digoxin toxicity.
Kaplan-Meier curves were plotted by age category for total
mortality and for the combination of HF death or HF
hospitalization. Multiple regression of survival data based
on the Cox proportional hazards model with backward
selection of covariates was used to determine independent
correlates of each outcome, both overall and within age
groups. Variables considered for inclusion in the model, in
addition to age category and treatment assignment, were:
cardiothoracic ratio, body mass index, ejection fraction,
serum creatinine, heart rate, systolic blood pressure, gender,
race, etiology of HF, prior myocardial infarction, diabetes
mellitus, hypertension, use of ACE inhibitors and New
York Heart Association functional class. All data are re-
ported as means (6 standard deviation) or as percentages.
RESULTS
Baseline characteristics. Baseline characteristics of pa-
tients in each of the five age groups are summarized in Table
1. Older patients were more likely to be women, to be
Caucasian and to take diuretics. They also had higher mean
systolic blood pressures, serum creatinine levels, cardiotho-
racic ratios on chest radiograph, New York Heart Associa-
tion functional classifications and LVEFs than younger
patients. The prevalence of diabetes mellitus and prior
myocardial infarction increased up to the seventh decade,
but then declined at older age. Use of ACE inhibitors
declined slightly at older age, but this could reflect the fact
that older patients were more likely to have an LVEF
.0.45.
Effect of age on mortality and hospitalizations. As shown
in Table 2 and Figures 1 and 2, increasing age was
associated with a progressive increase in the incidence of
death, hospitalization, HF hospitalization and HF death or
hospitalization (p for linear trend ,0.001 for each out-
come). Compared with patients ,50 years old, the adjusted
relative risk of death in patients over 80 years of age was
2.05. Similarly, the adjusted relative risk of hospitalization
for any reason was 1.55, the adjusted relative risk of
hospitalization for HF was 1.94 and the adjusted relative
risk for HF death or admission was 2.04.
Effect of digoxin on clinical outcomes by age group.
Table 2 also shows the effect of digoxin on mortality,
all-cause and HF hospitalizations and HF death or hospi-
talization in each age group. Consistent with the findings
from the primary DIG study analysis, digoxin had no effect
on total mortality, and there also was no interaction between
age and digoxin treatment with respect to this end point.
Similarly, whereas digoxin was associated with a modest
reduction in all-cause hospitalizations (6%), and more
substantial reductions in HF hospitalizations (27%) and in
HF death or hospitalization (24%), there was no interaction
between age and treatment assignment with respect to any
of these outcomes. Thus, digoxin was associated with a risk
reduction in HF death or hospitalization within each age
category, and the absolute reduction attributable to digoxin
therapy was 87 per 1,000 in individuals ,50 years of age
(p 5 0.12), 34 per 1,000 in patients 50 to 59 (p 5 0.0001),
62 per 1,000 in patients 60 to 69 (p 5 0.0001), 91 per 1,000
in patients 70 to 79 (p 5 0.0001) and 67 per 1,000 in
patients $80 years of age (p 5 0.20).
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
DIG 5 Digitalis Investigation Group
HF 5 heart failure
LVEF 5 left ventricular ejection fraction
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Adverse drug reactions. Table 3 shows mean digoxin
dosages and serum digoxin levels measured one month after
initiation of therapy in a randomly selected subset of DIG
study patients receiving active treatment. Despite an age-
related decline in mean dosage, mean digoxin levels tended
to be higher in older patients, although levels were within
the therapeutic range in all age groups. Table 4 characterizes
the frequency of side effects and suspected digoxin toxicity
throughout the follow-up period as a function of age and
treatment assignment. Data are based on reports filed by
study physicians at each local site. Electrocardiographic
tracings documenting arrhythmic events were obtained
when available, but specific details regarding nonfatal ar-
rhythmias (such as supraventricular tachycardias) were not
collected. Overall, 3.4% of patients were withdrawn from
study medication because of apparent side effects, and the
frequency of drug withdrawal increased progressively with
age, from 1.7% in patients ,50 years of age to 5.4% in
Table 2. Effect of Digoxin and Age Group on Clinical Outcomes
Age (yrs)
Overall
Main Effects* Interaction
of Trtmt
3 Age
Group
(p Value)<50 50–59 60–69 70–79 >80
Treatment Age Group
RR
(95% CI)
p
Value
RR
(95% CI)
p
Value
n 841 1,545 2,885 2,092 425 7,788
Digoxin 437 748 1,465 1,013 226 3,889 — — — — —
Placebo 404 797 1,420 1,079 199 3,899 — — — — —
Total mortality (%) 22.7 26.2 33.5 39.8 49.4 33.5
Digoxin 22.2 27.9 32.7 39.7 48.2 33.3 0.99 0.7815 1.28 0.0001 0.4534
Placebo 23.3 24.6 34.4 39.9 50.8 33.6 (0.92–1.07) (1.24–1.33)
All-cause hospitalization (%) 57.4 61.8 66.8 68.8 76.0 65.8
Digoxin 55.6 61.1 65.4 68.4 73.0 64.7 0.94 0.0166 1.13 0.0001 0.9305
Placebo 59.4 62.5 68.3 69.1 79.4 67.0 (0.89–0.99) (1.10–1.16)
HF hospitalization (%) 23.7 28.2 28.4 32.8 35.8 29.4
Digoxin 19.7 26.2 24.7 27.9 32.3 25.7 0.73 0.0001 1.15 0.0001 0.4443
Placebo 28.0 30.1 32.1 37.3 39.7 33.1 (0.67–0.79) (1.11–1.20)
HF mortality or HF
hospitalization (%)
25.7 31.1 31.5 37.1 41.6 32.8
Digoxin 21.5 29.3 28.4 32.4 38.5 29.4 0.76 0.0001 1.17 0.0001 0.4139
Placebo 30.2 32.7 34.6 41.5 45.2 36.2 (0.70–0.82) (1.13–1.22)
*Main effect p values reflect a model with no interaction term included as all interactions were not significant.
CI 5 confidence interval; HF 5 heart failure; RR 5 risk ratio.
Table 1. Baseline Characteristics of DIG Study Patients
Age (yrs)
<50 50–59 60–69 70–79 >80
Digoxin Placebo Digoxin Placebo Digoxin Placebo Digoxin Placebo Digoxin Placebo
n 437 404 748 797 1,465 1,420 1,013 1,079 226 199
Male 75% 77% 79% 77% 79% 80% 71% 71% 57% 57%
Nonwhite 26% 28% 16% 17% 13% 13% 10% 10% 12% 13%
Prior MI 45% 50% 64% 63% 67% 67% 66% 64% 56% 59%
Hypertension 43% 44% 43% 45% 48% 47% 50% 51% 48% 49%
Diabetes 19% 22% 29% 30% 32% 31% 28% 30% 17% 19%
Etiology
Ischemic 47% 53% 70% 65% 72% 73% 74% 72% 69% 68%
Nonischemic 53% 47% 30% 35% 28% 27% 26% 28% 31% 32%
Heart rate, min21 (mean) 81 82 81 82 78 78 77 78 78 78
Systolic BP, mm Hg (mean) 121 122 121 122 128 128 131 130 132 130
NYHA class
I–II 75% 75% 72% 72% 69% 69% 65% 66% 57% 55%
III–IV 25% 25% 28% 28% 31% 31% 35% 34% 43% 45%
CT ratio $ 0.55 33% 31% 31% 29% 31% 32% 36% 37% 49% 49%
Ejection fraction (mean) 30.5% 29.4% 30.5% 29.4% 31.8% 31.8% 33.1% 33.6% 36.6% 33.8%
Creatinine $ 1.7 mg/dl 4% 6% 6% 5% 13% 12% 20% 20% 25% 33%
Medications
Diuretics 77% 75% 79% 78% 79% 82% 85% 86% 89% 92%
ACE inhibitors 94% 96% 92% 96% 93% 94% 94% 92% 93% 91%
ACE 5 angiotensin-converting enzyme; BP 5 blood pressure; CT 5 cardiothoracic; DIG 5 Digitalis Investigation Group; MI 5 myocardial infarction; NYHA 5 New York
Heart Association.
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patients over the age of 80 (adjusted risk ratio 5 1.36, p 5
0.0001). However, because medication withdrawal in-
creased with age in both the digoxin and placebo groups,
there was no significant interaction between age and med-
ication withdrawal due to digoxin toxicity. Similarly, hos-
pitalizations for suspected digoxin toxicity increased with
age (adjusted risk ratio 5 1.31, p 5 0.0036), but there was
no significant interaction between age and hospitalization
for digoxin toxicity. With respect to specific side effects
associated with digoxin toxicity, atrioventricular block, su-
praventricular arrhythmias and nausea or vomiting all oc-
curred more frequently with advancing age, but again there
was no interaction between age and treatment assignment.
Of note, there was no apparent relationship between age
and the occurrence of visual disturbances or serious ventric-
ular arrhythmias.
Clinical outcomes by age and ejection fraction. Table 5
displays clinical outcomes based on age group, LVEF
category (#0.45 vs. .0.45) and treatment assignment. The
proportion of patients with preserved left ventricular systolic
function, as indicated by LVEF .0.45, increased signifi-
cantly with age, from 8.2% in patients under age 50 to
Figure 1. Kaplan-Meier curves illustrating the effect of age on total mortality.
Figure 2. Kaplan-Meier curves illustrating the effect of age on the combined end point of heart failure death or hospitalization.
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19.5% among patients over age 80. Total mortality was
significantly lower in patients with LVEF .0.45 in all age
groups (p 5 0.0001 overall; p , 0.05 within each age
group), and the absolute mortality difference was similar
across age groups. Hospitalizations for HF and the com-
posite end point of death or hospitalization for HF occurred
less frequently in patients with LVEF .0.45 (both p 5
0.0001), and absolute differences were again similar across
age groups. In contrast, all-cause hospitalizations did not
differ according to LVEF category (p 5 0.12), either overall
or within any specific age group.
Multivariate analysis. Table 6 lists independent predictors
of all-cause mortality based on a Cox proportional hazards
model. Increasing age, as defined by the five age categories,
was a strong independent predictor of total mortality, and
there was a 20% increase in mortality risk per decade.
Similarly, increasing age was an independent predictor of
all-cause hospitalizations, HF hospitalizations and the com-
posite of death or HF admission (data not shown). Digoxin
treatment was independently associated with lower all-cause
and HF hospitalization rates (p 5 0.0087 and p 5 0.0001,
respectively), as well as death or HF hospitalization (p 5
0.0001), but there was no effect of digoxin on total mortal-
ity.
DISCUSSION
Although the inotropic effect of digoxin is preserved at older
age (6), the volume of distribution declines with age, and it
has been suggested that older adults are at increased risk for
the development of digitalis intoxication and other adverse
side effects (7). Moreover, although withdrawal from
digoxin has been associated with clinical deterioration in
younger patients (8,9), it has been reported that many older
adults on chronic digoxin therapy can be safely withdrawn
without adverse consequences (10). In light of the fact that
the majority of HF patients are over 65 years of age, and
that the majority of digoxin prescriptions are written for
individuals in the older age groups, the safety and efficacy of
digoxin in the elderly are of great clinical relevance.
Safety. Although increasing age is associated with a modest
but progressive rise in the frequency of hospitalizations for
suspected digoxin toxicity and in the number of patients
withdrawn from therapy because of side effects, these trends
are apparent in placebo-treated as well as digoxin-treated
patients. As a result, older age was not associated with a
significant excess in the occurrence of digoxin toxicity
relative to placebo. Similarly, atrioventricular block, su-
praventricular arrhythmias and gastrointestinal symptoms
occurred more commonly in the elderly, both in the placebo
and treatment groups, but there was no age-related excess of
these adverse events in patients treated with digoxin. These
results are perhaps surprising, as older adults are often
considered to be at increased risk for digoxin toxicity (7),
and it has also been suggested that the therapeutic range for
digoxin may be shifted downward in the very elderly (6).
The findings of this study imply that side effects often
attributed to digoxin toxicity in older individuals may be due
to other causes, including age-related changes in atrioven-
tricular conduction, predisposition to supraventricular ar-
rhythmias and increased prevalence of nonspecific gastroin-
testinal disturbances. Thus, these findings are reassuring,
particularly considering that the incidence of hospitalization
for suspected digoxin toxicity was only 4.4% over a three-
year period in patients over 80 years of age, despite the fact
that digoxin levels were not routinely monitored in the DIG
study. This rate is considerably lower than earlier studies
indicating a 10% to 20% incidence of digitalis toxicity
during long-term therapy in elderly patients (7).
Efficacy. The DIG study demonstrated that digoxin re-
duced all-cause hospitalizations by 6%, HF hospitalizations
by 27% and the combined end point of HF death or
hospitalization by 24%, but there was no effect on total
mortality (4). The present analysis reveals that these find-
ings are consistent across all age groups, including the very
elderly. These findings support the view that digoxin is an
effective agent for the treatment of HF, even at very elderly
age.
HF with preserved systolic function. Heart failure with
preserved systolic function accounts for 30% to 50% of all
cases of HF, and the prevalence of this disorder increases
with age (11,12). In the DIG study, patients with an LVEF
.0.45 comprised only 12.7% of the total population, most
likely reflecting the fact that many physicians consider
preserved LVEF to be a contraindication to the use of
digoxin for the treatment of HF. Compared to patients with
reduced LVEF, the etiology of HF in DIG study patients
with preserved LVEF was less likely to be ischemic (71 vs.
57%, p , 0.001). Despite the relatively low enrollment of
patients with preserved systolic function, the proportion of
patients with this syndrome increased progressively with
age, from 8.2% in patients ,50 years to 19.5% in patients
over 80 years. Notably, the incidence of all major outcomes
increased with advancing age, regardless of whether the
LVEF was , or .0.45. In addition, although the prognosis
with respect to both mortality and admission for HF was
somewhat better in patients at all ages with preserved
LVEF, there was no difference in all-cause hospitalizations
as a function of LVEF. These findings are consistent with
other studies indicating that LVEF predicts mortality, but
Table 3. Mean Digoxin Dose Prescribed and Mean
Serum Digoxin Levels by Age Group at One Month
After Randomization*
Age Group (yrs) n
Digoxin Dose
Prescribed
Mean 6 SD
Serum Digoxin Levels
Mean 6 SD Range
,50 199 0.29 6 0.09 0.78 6 0.44 0–2.7
50–59 380 0.27 6 0.07 0.79 6 0.49 0–3.2
60–69 740 0.24 6 0.06 0.91 6 0.54 0–4.1
70–79 462 0.21 6 0.06 0.98 6 0.45 0–3.1
$80 79 0.18 6 0.07 0.93 6 0.44 0–2.9
Overall 1,860 0.24 6 0.07 0.89 6 0.50 0–4.1
*Data exclude levels obtained within 6 h of a digoxin dose.
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that it correlates poorly with either symptom severity (such
as New York Heart Association functional class) (13) or
functional capacity (such as VO2max) (14).
Clinical implications. The results of these analyses indi-
cate that age should not be a major factor in determining
when to use digoxin for the treatment of HF. However,
because side effects potentially due to digoxin therapy occur
more commonly in older individuals, it is important to
monitor therapy more closely. In addition, lower dosages of
digoxin may be prudent in the very elderly, especially
because the therapeutic range may be lower, and recent data
suggest that there is no additional benefit from higher doses
(15). With respect to HF with preserved LVEF, results
from the DIG ancillary study indicate that digoxin may be
useful in selected patients with this condition (4). However,
additional data are needed, particularly in the very elderly,
before digoxin can be recommended as routine therapy in
patients with HF and preserved LVEF.
Study limitations. Randomization in the DIG study was
not stratified by age, and there were relatively few patients
over 80 years of age enrolled in the trial. In addition,
although up to two-thirds of all HF patients in the general
population are over age 70, only 32% of DIG study patients
were in this age group, indicating a significant selection bias
in patient recruitment. Importantly, the exclusion of pa-
tients with atrial fibrillation, which increases in prevalence
with advancing age, likely contributed to this selection bias.
The DIG study also enrolled an insufficient number of
elderly racial and ethnic minority group subjects to permit
firm conclusions about the safety and efficacy of digoxin in
these subgroups. In light of these considerations, the study’s
findings may not be generalizable to elderly HF patients in
the community.
Conclusions. Increasing age is a strong independent pre-
dictor of total mortality, hospital admissions, HF death or
hospitalization and suspected adverse reactions to digoxin in
patients with HF. However, the effects of digoxin on clinical
outcomes are independent of age, and digoxin remains a
useful adjunctive agent for the treatment of HF associated
with reduced left ventricular systolic function in patients of
all ages. The role of digoxin in HF patients with preserved
systolic function requires further study.
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Table 6. Cox Proportional Hazard Model Analysis to
Determine the Effect of Age and Treatment on All-Cause
Mortality (n 5 7,746)*
Variable RR 95% CI p Value
Increasing age group† 1.199 1.150–1.249 0.0001
Cardiothoracic ratio (per 1% chg) 13.941 8.117–23.941 0.0001
Body mass index (per 1-point chg) 0.982 0.974–0.990 0.0001
Left ventricular ejection fraction
(per 1% chg)
0.984 0.980–0.987 0.0001
Serum creatinine (mg/dl) 1.826 1.658–2.011 0.0001
Systolic blood pressure (mm Hg) 0.995 0.993–0.997 0.0001
Male gender 1.202 1.088–1.329 0.0003
History of diabetes 1.401 1.289–1.523 0.0001
New York Heart Association
functional class
1.360 1.283–1.441 0.0001
*Of 7,788 patients, there were missing values in 42 patients; †age groups are ,50,
50–59, 60–69, 70–79, $80 years.
CI 5 confidence interval; RR 5 risk ratio.
813JACC Vol. 38, No. 3, 2001 Rich et al.
September 2001:806–13 Age and Clinical Outcomes in the DIG Study
